Turk Ilac Ve Serum Sanayi Anonim Sirketi

IBSE:TRILC Stock Report

Market Cap: ₺3.5b

Turk Ilac Ve Serum Sanayi Anonim Sirketi Past Earnings Performance

Past criteria checks 0/6

Turk Ilac Ve Serum Sanayi Anonim Sirketi's earnings have been declining at an average annual rate of -2.7%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 27.9% per year.

Key information

-2.69%

Earnings growth rate

11.37%

EPS growth rate

Pharmaceuticals Industry Growth12.39%
Revenue growth rate27.87%
Return on equity-10.53%
Net Margin-6.98%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Turk Ilac Ve Serum Sanayi Anonim Sirketi makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

IBSE:TRILC Revenue, expenses and earnings (TRY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 252,730-1912890
31 Dec 242,568722690
30 Sep 241,6822561760
30 Jun 241,9461991730
31 Mar 241,615881660
31 Dec 232,7741532340
30 Sep 232,893-2222510
30 Jun 232,383-1392210
31 Mar 232,175-1031930
31 Dec 221,637-821710
30 Sep 2282531940
30 Jun 2281213720
31 Mar 2276037580
31 Dec 2167337400
30 Sep 2155465370
30 Jun 2142686350
31 Mar 2121851270
31 Dec 2020033270
30 Sep 2021952260
31 Dec 1915213210
31 Dec 189714130
31 Dec 17538110

Quality Earnings: TRILC is currently unprofitable.

Growing Profit Margin: TRILC is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TRILC is unprofitable, and losses have increased over the past 5 years at a rate of 2.7% per year.

Accelerating Growth: Unable to compare TRILC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRILC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.6%).

Return on Equity

High ROE: TRILC has a negative Return on Equity (-10.53%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 10:40
End of Day Share Price 2025/05/20 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Turk Ilac Ve Serum Sanayi Anonim Sirketi is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.